2 citations
,
January 2025 in “Journal of Oncology Pharmacy Practice” Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.
January 2012 in “Journal of Clinical Medicine in Practice” The treatment is safe and effective for elderly patients with advanced non-small-cell lung cancer.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
April 2026 in “Nowotwory Journal of Oncology” Aesthetic treatments can safely improve cancer patients' quality of life with oncologist approval.
January 2022 in “eJournal Kedokteran Indonesia” Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
15 citations
,
July 2023 in “EClinicalMedicine” ADCs can effectively treat breast cancer but may cause side effects like nausea and hair loss.
5 citations
,
January 2024 in “Therapeutic Advances in Hematology” Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.
August 2025 in “MedScien” Tumor-targeted drug carriers can improve chemotherapy precision and reduce side effects.
December 2023 in “Frontiers in oncology” Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.
January 2024 in “Faculty of 1000 Research Ltd” Most pediatric cancer patients at Muhimbili National Hospital experienced adverse drug reactions during chemotherapy, highlighting the need for careful monitoring.
Cetirizine-loaded gel may effectively promote hair growth in alopecia.
May 2022 in “Голова и шея.” Exosomes show promise for targeted treatment of HER2-positive breast cancer.
12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
4 citations
,
April 2024 in “Journal of Drugs in Dermatology” Ruxolitinib cream may help treat severe hair loss in children.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
12 citations
,
November 2017 in “European Annals of Allergy and Clinical Immunology” Omalizumab can cause temporary hair loss but still works well for chronic urticaria.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
56 citations
,
September 2016 in “Pharmaceutical Research” The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.
1 citations
,
January 2024 in “Arab Board Medical Journal” Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
1 citations
,
January 2020 in “Surgical & Cosmetic Dermatology” Combining oral minoxidil with JAK inhibitors helps regrow hair in severe alopecia areata cases.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
5 citations
,
June 2005 in “Journal of Clinical Oncology” PPX causes much less hair loss than traditional taxanes.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
5 citations
,
February 2016 in “International Journal of Cancer” Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.